Zenas BioPharma, Inc.

NASDAQ:ZBIO

Biotechnology

Healthcare
$26.42 +3.46%

+$0.64 today

Market cap
$1.79B
Beta
-0.69
P/E (TTM)
-2.5
EPS (TTM)
-$7.64
52W Low $8.91High $44.60

Volume 0.48M

Average 0.71M

ZBIO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Zenas BioPharma, Inc.NASDAQ: ZBIO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Context

  • Gross margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+2782.8 pp YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+2782.8 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+2782.8pp

Gross Margin vs competitors

How ZBIO compares with its peers on the latest reported figures

  • ZBIO's FY2025 gross margin of 100.0% is the highest of the 5 companies compared; the peer median is 98.9%.
  • Its year-over-year change of +2782.8 pp is the highest of 3, against a peer median of +27.2 pp.
ZBIO Competitors Peer median
Gross Margin for ZBIO and competitors
Company Period LTM level YoY 3-year change
ZBIOZenas BioPharma, Inc.FY2025100.0% +2782.8 pp—
IMVTImmunovant, Inc.LTM Sep 2026100.0% ——
QTTBQ32 Bio Inc.LTM Mar 202699.3% —-0.7 pp
UPBUpstream Bio, Inc.LTM Mar 202698.5% -1.5 pp+0.0 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
ANNXAnnexon, Inc.FY2025— ——
TLSATiziana Life Sciences LtdFY2025— ——
Peer median (excluding ZBIO) 98.9%+27.2 pp+0.0 pp

Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050M5M10M
Cost of Revenue61.69M0139.14M0
Gross Profit(61.69M)50M(134.14M)10M
Gross Margin—100.0%-2682.8%100.0%
Research & Development62.69M60.03M139.14M168.06M
Selling, General & Admin13.51M17.11M29.75M53.32M
Operating Expenses14.51M87.15M29.75M221.39M
Depreciation & Amortization78K113K137K56K
EBITDA(75.12M)(27.03M)(156.42M)(370.43M)
EBITDA Margin—-54.1%-3128.4%-3704.3%
Operating Income(76.2M)(37.15M)(163.89M)(211.39M)
Operating Margin—-74.3%-3277.8%-2113.8%
Interest Income00012.15M
Interest Expense0007.33M
Other Income / Expenses(43.08M)324K7.33M(166.43M)
Income Before Tax(119.28M)(36.82M)(156.56M)(377.82M)
Pre-Tax Margin—-73.6%-3131.2%-3778.2%
Income Tax Expense0301K429K(79K)
Net Income(119.28M)(37.12M)(156.99M)(377.74M)
Net Margin—-74.2%-3139.8%-3777.4%
EPS (Basic)(3.11)(0.97)(3.76)(8.44)
EPS (Diluted)(3.11)(0.97)(3.76)(8.44)
Weighted Avg Shares38.32M38.32M41.79M44.73M
Weighted Avg Shares (Diluted)38.32M38.32M41.79M44.73M

Zenas BioPharma, Inc.

NASDAQ:ZBIO

Intrinsic Alpha fair value

Locked

Current Price

$26.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.